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Abstract
Background: In recent years the interest on the relationship of gut hormones to bone processes has increased
and represents one of the most interesting aspects in skeletal research. The proportion of bone mass to soft tissue
is a relationship that seems to be controlled by delicate and subtle regulations that imply “cross-talks” between the
nutrient intake and tissues like fat. Thus, recognition of the mechanisms that integrate a gastrointestinal-fat-bone
axis and its application to several aspects of human health is vital for improving treatments related to bone
diseases. This work analysed the effects of gut hormones in cell cultures of three osteoblastic cell lines which
represent different stages in osteoblastic development. Also, this is the first time that there is a report on the direct
effects of glucagon-like peptide 2, and obestatin on osteoblast-like cells.
Methods: mRNA expression levels of five gut hormone receptors (glucose-dependent insulinotropic peptide [GIP],
glucagon-like peptide 1 [GLP-1], glucagon-like peptide 2 [GLP-2], ghrelin [GHR] and obestatin [OB]) were analysed
in three osteoblastic cell lines (Saos-2, TE-85 and MG-63) showing different stages of osteoblast development using
reverse transcription and real time polymerase chain reaction. The responses to the gut peptides were studied
using assays for cell viability, and biochemical bone markers: alkaline phosphatase (ALP), procollagen type 1 amino-
terminal propeptides (P1NP), and osteocalcin production.
Results: The gut hormone receptor mRNA displayed the highest levels for GIP in Saos-2 and the lowest levels in
MG-63, whereas GHR and GPR39 (the putative obestatin receptor) expression was higher in TE-85 and MG-63 and
lower in Saos-2. GLP-1 and GLP-2 were expressed only in MG-63 and TE-85. Treatment of gut hormones to cell
lines showed differential responses: higher levels in cell viability in Saos-2 after GIP, in TE-85 and MG-63 after GLP-1,
GLP-2, ghrelin and obestatin. ALP showed higher levels in Saos-2 after GIP, GHR and OB and in TE-85 after GHR.
P1NP showed higher levels after GIP and OB in Saos-2. Decreased levels of P1NP were observed in TE-85 and MG-
63 after GLP-1, GLP-2 and OB. MG-63 showed opposite responses in osteocalcin levels after GLP-2.
Conclusions: These results suggest that osteoblast activity modulation varies according to different development
stage under different nutrition related-peptides.
Background
Bone is a tissue subjected to constant forces and remo-
delling, requiring a satisfactory nutrient intake to main-
tain bone mass. It has previously been suggested that
there is a direct association between food intake and
bone turnover as assessed by biochemical markers of
bone resorption and formation [1,2]. Some observations
indicate that there are other mechanisms regulating the
interaction between nutrition and bone homeostasis, in
addition to those well studied processes involving vita-
min D or parathyroid hormone (PTH) [3].
Among the alternative regulatory mechanisms, hor-
mones produced in the gastro-intestinal tract may play
an essential role. These gastro-entero-pancreatic hor-
mones are important gastrointestinal-releasing hor-
mones involved in the regulation of postprandial
nutrient homeostasis [4]. The interest in gut hormones
and their relationship to bone metabolism has been
increasing, presenting the possibility of alternative
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The connection between gut hormones and bone has
been cited as an entero-osseous-axis [5] to resemble the
term entero-insular axis, which refers to the signalling
pathways between the gut and pancreatic islets that
enhance the insulin response to absorbed nutrients [6].
The present study is focused on five of these gut hor-
mones and their effects on osteoblast-like cell lines: two
incretin hormones glucose-dependent insulinotropic pep-
tide (GIP), glucagon-like peptide 1 (GLP-1), the related
glucagon-like peptide 2 (GLP-2), and the two preprogh-
relin gene products, ghrelin (GHR) and obestatin (OB).
Previous studies have shown that GIP is able to
increase collagen type I expression and alkaline phos-
phatase (ALP) activity in osteosarcoma cell lines (Saos-
2, MG-63, ROS 17/2.8) [7], and to a certain extent has a
protective effect on osteoblast apoptosis [8]. The role of
GIP in modulation of bone turnover has been studied
using knockout mice models, and the results showed
less bone formation, smaller bone size, lower bone mass
alterations in bone microarchitecture and biomechanical
properties, in GIP receptor knockout mice [9]. Another
study has shown that GIP inhibited resorptive activity of
osteoclasts [10].
Reports of GLP-1 effects on bone metabolism are lim-
ited and, equivocal. Although, receptors for GLP-1 had
not been demonstrated in human osteoblasts it has been
suggested that these receptors could be vital for some
processes in bone turnover, especially those related to
resorption [11,12]. Moreover, a functional receptor for
GLP-1 using a pathway non-dependant of cAMP has
been reported in a murine osteoblastic cell line [13].
Among other actions, GLP-1 has an important role in
apoptosis, differentiation and intracellular effects on cal-
cium in human pancreatic islet cells [14,15].
A number of studies have demonstrated a clearer rela-
tionship between GLP-2 and bone metabolism. A study
showed that patients, with small-bowel resection and
colon resection receiving a subcutaneous dose of GLP-2
had positive effects on their bone mineral density
(BMD) but the levels of the bone turnover markers did
not clarify on the involved mechanisms [16].
Henriksen et al [17] studied postmenopausal women
in randomized placebo-controlled studies and showed
that GLP-2 transiently suppressed the nocturnal rise in
b-CTX compared to control. In the same report [17] a
dose-dependent effect of GLP-2 on bone formation was
observed. In both cases, there were significant reduc-
tions in b-CTX. In addition, the authors measured
osteocalcin and this was increased compared to placebo,
indicating a dose-dependent effect of GLP-2 on bone
formation.
Ghrelin is an endogenous ligand for GHS-R, which
has been purified and characterized, and acts as an
agonist for an orphan receptor [18]. The data suggest
that ghrelin signalling may be essential for normal
growth in humans and some authors have reported a
significant stimulation of osteoblast proliferation and an
increased ALP activity in osteoblasts in response to
ghrelin [19,20], and a suspected direct regulation of
bone formation [21].
Based on data provided by bioinformatics, a ghrelin-
associated peptide was identified and called obestatin. In
in vitro observations this peptide, unlike ghrelin, did not
increase growth hormone secretion by cultured rat
pituitary cells [22], however other investigations have
shown that obestatin is capable of growth hormone
modulation in growth cells from a rat somatotroph
tumour [23].
To date, no available information on the effects of
obestatin on bone metabolism is available. Its receptor
is believed to be an orphan receptor G-coupled protein
(GPR-39) [22], although some discrepancies have been
reported, in which GPR39 could not be activated by
obestatin but by high concentrations of zinc ions
[24,25], although more recent studies demonstrated that
transfected cells with a plasmid encoding GPR39 exhib-
ited high -affinity binding to an analogue of obestatin
(monoiodobestatin) [26].
This study investigated the expression of five gut
hormone receptors (GIP-R, GLP-1R, GLP-2R, ghrelin
receptor [GHS-R] and GPR39) when RNA from three
osteoblastic cell lines was extracted, reverse tran-
scribed and analysed using real time amplification. In
addition, the expression of collagen 1 alpha 2
(COL1A2), ALP and OPG was included to profile
some features of these cell lines. The functional
responses to increasing concentrations of these hor-
mones, on all three osteoblast cell lines are reported
in terms of cell viability levels, ALP activity, N-term-
inal propeptide of type I procollagen (P1NP) and
osteocalcin determinations in culture supernatants.
The cell lines used in the present model exhibits the
following background:
MG-63. It is a cell line derived from an osteosarcoma.
They are considered to display features of an undifferen-
tiated early osteoblast phenotype. These cells produce
high amounts of interferon, and provide suitable models
for studying comparable integrin subunit expression and
osteocalcin production to those in primary bone cells,
b u tt h e ya r en o tg o o dm o d e l sf or proliferation (higher
rate), ALP (poor production) or osteonectin production
[27,28].
TE-85. Referred to as HOS or TE-85, they were
derived from the sarcoma of a female Caucasian. These
cells have a higher production of ALP than MG-63, but
a low synthesis of osteocalcin. As MG-63, they are suita-
ble models to study integrins [27].
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Caucasian. These cells are excellent producers of ALP,
but osteocalcin is poorly produced in these cells. They
are highly sensitive to PTH stimulation [29]
Methods
Cell culture of the osteoblastic-like cell lines
Three cell lines were used: Saos-2, TE-85, and MG-63.
All of them were grown in DMEM (Sigma, UK) supple-
mented with 10% fetal calf serum (FCS) (Biosera, UK),
50 U/ml penicillin, 50 μg/mL streptomycin. For the
study of the receptors cells were grown near confluence
in 9-cm Petri dishes. For the functional studies, the cells
from the second passage were seeded for 24 hours in
24-well plates, and serum deprived for 24 hours. After
this time the medium was changed for modified med-
ium supplemented with gut hormones, in different con-
centrations depending on the experiments to be
performed. After the exposure to peptides, the assays
were performed for cell viability, ALP, P1NP and osteo-
calcin secretion. Cells growing in medium without any
of the gut peptides were used as controls. The experi-
ments were set individually per cell line. The arrange-
ment of wells was randomized within the plates to avoid
“edge-effects”. The gut peptides used were human GIP,
GLP-1 (7-36) amide, GLP-2 purchased from PolyPeptide
Laboratories GmbH, Wolfenbüttel, Germany. Human
ghrelin (octanoyl) and obestatin Gly-Lys were obtained
from Phoenix Europe GmbH (Karlsruhe, Germany).
Reverse transcriptase polymerase chain reaction (RT-PCR)
The presence of expressed receptors was detected by
extraction and reverse transcription of RNA obtained
from confluent cell cultures. Briefly, the standard proto-
col is as follows: Tri reagent-chloroform was used to
extract mRNA and reverse transcribed, with Superscript
II (Invitrogen, UK) to obtain the cDNA first strand.
PCR screening was performed in a MJ Research thermal
(Labcare, UK) cycler using a 10 μl reaction volume con-
taining cDNA, dNTPs, PCR buffer with added MgCl2,
the appropriate oligonucleotide primers of each receptor
gene and Hot Start
® taq polymerase. The protocol used
the following cycles: initial denaturation for 15 min, fol-
lowed 40 cycles of denaturation (20 sec), annealing (40
sec), and extension (40 sec), and a final extension cycle
(5 min). The reaction products were separated on a 1%
agarose gel in Tris-borate-EDTA buffer, containing
SYBR safe (Invitrogen), and were run at 100 volts.
Real-time RT-PCR quantitation (RT-qPCR) of gene
expression
In order to compare the rates of the gene relative
expression, RT-qPCR was performed and monitored
using iCycler iQ (Bio-Rad, UK) following the protocol
recommended by the manufacturer. cDNA samples
were analyzed both for the genes of interest (gut hor-
mone receptors) and the reference gene (b-actin). The
cycling program was as follows: denaturing at 95°C for 3
min followed by 40 cycles of annealing and denaturing
for 30 s. Reactions were done in triplicate on a 96-well
plate in two different runs. Cycle threshold (Ct) values
were obtained and efficiency parameter was calculated
with LinRegPCR software for each well. Both parameters
were used to calculate the relative rate expression for
each gene of interest using b-actin as a normalizer [30].
The primer oligonucleotide sequences are shown in
Table 1.
Viability assay
The assay for viability was performed, using a fluoro-
genic, cell permeant, peptide substrate (glycil-phenylala-
nyl-amino-fluorocoumarin,[ G F A F C ] ,P r o m e g a ) .C e l l s
were seeded into 96-well black wall plate (clear bottom),
at a density of 10,000 cells per well in 100 μLm e d i u m ,
s e r u md e p r i v e d2 4h ,a n dt r e a t e dw i t ht h eg u tp e p t i d e s
at final concentrations from 10
-12 to 10
-9, using 10 repli-
cates per concentration per peptide. The viable cell pro-
tease marker assays were conducted using GF-AFC at
10
-4M final concentration (as recommended by the
manufacturer). Readings for relative units of fluores-
cence were obtained using the Cytofluor series 4000
equipment (Applied Biosystems), filters for excitation
~400 nm, and emission ~505 nm (photomultiplier gain
factor 40).
ALP activity
ALP was measured in culture supernatants using a pro-
cedure which involves a colorimetric assay using p-
nitrophenyl phosphate as substrate, and measuring spec-
trofotometrically the p-nitrophenol released at 405 nm
with the absorbance being proportional to the ALP
activity. Cells were seeded onto 24 well plates and cul-
tures were treated with the gut peptides at final concen-
trations ranging from 10
-12 to 10
-9 M and supernatants
were collected for further ALP assay. The determina-
tions were performed using 10 replicates each time. All
the treatments were compared against control wells (cell
culture with ordinary DMEM without hormone
peptides).
P1NP assay
The assay was performed using an electrochemilumines-
cence immunoassay (ECLIA) in an Elecsys Immunoassay
System (Roche) and measures both monomeric and tri-
meric forms of P1NP. Cells were treated with gut pep-
tides at two final concentrations of 10
-11 and 10
-9 M,
five replicates were used per treatment, and superna-
tants were collected to perform the determinations.
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This determination was performed using ECLIA, and
measures N-terminal midfragment osteocalcin. Cells
were treated as in the latter assay: gut peptides were
added at two final concentrations of 10
-11 and 10
-9 M,
five replicates were used per treatment, and superna-
tants were collected to perform the determinations.
Statistical analysis
Data obtained in viability, ALP, P1NP, and osteocalcin
assays were analyzed with SPSS software, using the test
of Levene to assess the equality of variances. The signifi-
cance was set at P-values less than 0.05. Student’st - t e s t
was used to compare individually the means of each
treatment. Results are shown as the fold or percentage
changes plus-minus standard error of the mean (SEM)
Results
Expression of gut hormone receptors detected by PCR
mRNAs were extracted from the three osteoblastic cell
lines (MG-63, TE-85, Saos-2), and treated with DNAse
to remove traces of genomic DNA contamination and
followed by reverse transcription. The mRNA level was
quantitated by RT-qPCR using designed primers for all
the genes of interest (two bone markers and five gut
hormone receptors). b-actin was used as the housekeep-
ing gene to standardise between samples.
The RT-qPCR procedure was performed to study
mRNA expression levels for COL1A2, ALP, OPG and
the gut hormone receptors. The results showed that
COL1A2, ALP and OPG had the highest expression in
Saos-2, and the lowest in MG-63. COL1A2 mRNA
levels demonstrated rates of 4 and 4.7 times in TE-85
and Saos-2, respectively, over MG-63 (Figure 1A). ALP,
showed rates of 5.2 and 8 times in TE-85 and Saos-2
over MG-63 (Figure 1B). OPG was also best expressed
in TE-85 and Saos-2, with rates of 2.5 and 2.6 respec-
tively over MG-63 (Figure 1C). From these determina-
tions a pattern was observed, in which Saos-2 is
identified as the cell line being the most mature or dif-
ferentiated and MG-63 as the least differentiated. TE-85
may have a level of maturity somewhere between MG-
63 and Saos-2.
mRNA relative expression for each gut hormone
receptor genes, showed that GIP-R was in direct relation
with the differentiation degree, thus the most mature
cell line, Saos-2, had the greatest level of expression and
it was decreasing according to the maturity level (Figure
1D). The rates of GIP-R expression for Saos-2 were
about 9 times greater than MG-63 and 2 times those
expressed in TE-85.
In the case of GLP-1R (Figure 1E) and GLP-2R (Fig-
ure 1F), their expression was observed in TE-85 and
MG-63, but it could not be confirmed in Saos-2. GLP-
1R in TE-85 displayed higher levels of mRNA level,
whereas GLP-2R had a higher level in MG-63, but no
major differences were observed between TE-85 and
MG-63. GHS-R showed greater expression in the least
mature cell lines, 5 fold higher than the lower expres-
sion in Saos-2 (Figure 1G). GPR-39 followed an inverse
relation with the maturity degree, with the highest
expression in MG-63 and the lowest expression in Saos-
2 (Figure 1H). The specificity of the RT-qPCR was
further confirmed with the analysis of the melting
curves, set after the standardised 40 cycles of
amplification.
Figure 2 summarises the findings for the receptors per
cell line. After calculations for the level of expression
Table 1 Details of primer sequences used in qPCR analysis
Gene of interest Accesion numbers Sequence of primers Product size Annealing temp (°C)
COL1A2 NM_000089 5’ GGCACTCCAGGTCCTCAG 3’
5’ CCACAGCACCAGCAACAC 3’
100 60
ALP NM_000478 5’ GCTGAACAGGAACAACGTGA3’
5’ TCAATTCTGCCTCCTTCCAC 3’
117 60
OPG NM_002546 5’GCAGCGGCACATTGGACATG
5’AGGATCTGGTCACTGGGTTTGC3’
135 60
b-ACTIN NM_001101 5’ GGACCTGACTGACTACCTC 3’
5’ GCCATCTCTTGCTCGAAG 3’
135 60
GIPr NM_000164 5’ GACCAAAGGCTCATCTTGGA 3’
5’ ATGTAGCCGCCTGAACAAAC 3’
114 60
GLP-1r NM_002062 5’ TGGACCAGGAACTCCAACAT 3’
5’ TTTGGATACCACGATGCAGA 3’
114 62.5
GLP-2r NM_004246 5’ TTCCTTTATTGGGCGTTCA 3’
5’ CTCTCCATTGGCAAAACCA 3’
155 60
GHSr 1a NM_198407 5’ GCACTCTTCGTGGTGGGCAT 3’
5’ GATGAGCAGATCGGAGAAGG 3’
123 60.5
GPR39 NM_001508 5’ GCTCATGAAAAGCCAGAAGG 3’
5’ CATGATCCTCCGAATCTGGT 3’
172 60
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Figure 1 COL1A2, ALP, OPG and gut hormone expression profiles. After extraction and reverse transcription, mRNA levels were analysed.
Results are expressed as means of at least six replicates per cell line ±SEM. b-actin was used as the housekeeping gene to normalize the levels
of mRNA expression. In all the cases these determinations showed highest expression in Saos-2 and the lowest rate was for MG-63. Water was
used as non-template control. COL1A2, ALP and OPG had their highest expression in Saos-2, and the lowest in MG-63. GIP-R, GHS-R, and GPR39
mRNA expression was found in the three osteoblastic cell lines. GLP-1R and GLP-2R expression was observed only in MG-63 and TE-85.
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highest point for each cell line, and assigning it the arbi-
trary value of 1, to find the profile per cell line. This
analysis shows that GLP-1R and GLP-2R were most
expressed in MG-63 and TE-85, but GIP-R was
preferentially expressed in Saos-2, leaving GHS-R and
GPR39 with the lowest level of expression for the three
cell lines.
Cell viability, ALP, P1NP and osteocalcin assays Viability
assay
In general, the viability test showed unaffected or signifi-
cant higher changes levels of cell viability after exposure
to peptides. GIP did not cause any significant changes in
MG-63 or TE-85 viability, although the trend was on the
increase at 48 h exposure (Figure 3A, B). Conversely, in
Saos-2, no changes were observed after 48 h, but a statis-
tically significant dose-dependent increase was observed
after 120 h of exposure to the peptide (10
-11Mp=0 . 0 0 1 ,
10
-10M p = 0.002, 10
-9M p < 0.001) (Figure 3C).
GLP-1 caused significant increases in cell viability in
MG-63 at 10
-10 M (p = 0.011) and 10
-9 M (p = 0.040)
(Figure 3D). In TE-85 significant changes were observed
at 10
-10 M (p = 0.048) (Figure 3E). In both cases the sig-
nificant responses were registered at 48 h. Saos-2 did
not exhibit any changes after exposure to this peptide
(Figure 3F). In the case of GLP-2, significant changes
were observed in the viability of MG-63 (p = 0.001)
(Figure 3G) and TE-85 (p = 0.040) (Figure 3H), with
increases after 48 h, at 10
-12M but no other changes
were observed at higher concentrations or extended
treatment times. Saos-2 did not display any changes in
response to this peptide in the viability test (Figure 3I).
GHR induced a significant increase in MG-63 (Figure
3J) viability at its highest concentration (p = 0.014) after
48 h of exposure. Also, TE-85 (Figure 3K) displayed sig-
nificant increases at 10
-10M (p = 0.037) and 10
-9M( p=
0.046) after 48 h in the viability test, but no changes were
observed after 120 h. Saos-2, did not exhibit any change
(Figure 3L). OB caused significant changes increasing the
viability in TE-85 (Figure 3N) at 10
-12M after 48 h (p =
0.030). MG-63 and Saos-2 (Figure 3M, O) did not show
changes in viability after exposure to this peptide.
ALP production
In terms of significant ALP activity changes in superna-
tants induced by the presence of gut hormones, GIP,
GHR an OB caused significant increases in Saos-2 and
TE-85 (only with GHR).
GIP did not have any effect on ALP production by
MG-63 (Figure 4A) or TE-85 (Figure 4B), but it caused
significant increases that were dose-dependent in ALP
production by Saos-2 (Figure 4C) after 48 and 120 h.
The significant changes observed at 48 h were at 10
-11M
(p = 0.035), 10
-10M (p < 0.001) and 10
-9M (p < 0.001);
for 120 h the significant increases were observed starting
with the lowest concentration: 10
-12M (p = 0.043), 10
-
11M (p < 0.001), 10
-10M( p<0 . 0 0 1 )a n d1 0
-9M( p<
0.001).
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Figure 2 Expression of the gut hormone receptors in cell lines.
After normalizing mRNA levels to b-actin, they were re-normalized
again to the gene which presented the highest rate in each cell
line, in order to display a profile for each cell line. This normalisation
showed that GLP-1r and GLP-2r have a higher expression in MG-63
(A); GLP-1r is predominantly in TE-85 (B); GIPr is the most important
in Saos-2 (C); and GHSr and GPR39 have the lowest expression in
the three cell lines (A,B,C). Data are presented as the means of
normalized data ± SEM.
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GLP-2 in any of the cell lines (Figures 4D-1)
GHR did not cause any changes in ALP production by
MG-63 (Figure 4J). However, the presence of this pep-
tide caused significant increases in ALP production by
TE-85 (Figure 4K) and Saos-2 (Figure 4L) when the
highest concentration (10
-9M) was present in the culture
medium at the two time points investigated. For TE-85,
p < 0.001 at 48 h and p = 0.018 at 120 h. In the case of
Saos-2, p = 0.035 at 48 h, and p = 0.040 at 120 h.
Even though OB did not cause any significant
increases in ALP activity in MG-63 (Figure 4M) and
TE-85 (Figure 4N), Saos-2 displayed a significant
response after 120 h at 10
-10M (p = 0.032), and a bell-
shaped like curve was observed after 48 h (Figure 4O).
P1NP secretion
GIP did not cause any significant changes in MG-63 in
P1NP production (Figure 5A). In TE-85 a significant
decrease in P1NP secretion was observed after 120 h
exposure with the two concentrations tested, 10
-11M
and 10
-9M, (p = 0.003 and p = 0.002 respectively) (Fig-
ure 5B). Conversely, GIP significantly increased P1NP
secretion by Saos-2 cells at 10
-11Ma f t e r1 2 0h( p=
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Figure 3 Cell viability levels after treatments with gut hormones in three osteoblastic cell lines. Cells were treated for 48 or 120 h with
the gut peptides at indicated molar concentrations. Straight lines solid diamond markers designate 48 h treatment; dashed lines emptied
diamond markers indicate 120 h treatment. In this assay, GIP induced statistically significant increases in Saos-2 after 120 h in a dose-dependent
manner (C), GLP-1 (D,E), GLP-2 (G, H)) and GHR (J, K) caused increases in MG-63 and TE-85, and the only positive responses for OB were
observed in TE-85 (N). Results are the average of percentage of change in relation to controls; n = 10. ± SEM.
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Page 7 of 140.019), but no differences were observed at the highest
concentration at any time (Figure 5C).
GLP-1 induced in MG-63 a significant decrease in
P1NP secretion after 120 h at 10
-11Ma n d1 0
-9M( p=
0.033 and p = 0.007, respectively) (Figure 5D). Also, TE-
85 exhibited significant decreases after 120 h, at both
concentrations (p = 0.004, p = 0.043) (Figure 5E). Saos-
2 did not display any significant differences at any point
(Figure 5F).
GLP-2 only caused significant changes in P1NP secre-
tion by TE-85 cells after 120 h when the concentration
was 10
-11M (p = 0.003) (Figure 5H). No statistically
significant alterations were observed in MG-63 (Figure
5G) or Saos-2 cultures (Figure 5I) when they were trea-
ted with GLP-2.
In the case of GHR, no significant changes were
observed after treatment with this peptide in any of the
cell lines (Figure 5J-L).
OB caused opposite actions in two of the cell lines: in
TE-85 there was a significant decrease after 120 h at 10
-
11M (p = 0.030) (Figure 5N), but in Saos-2 the levels of
P1NP were increased above 25% of change from control
at 10
-11M (p = 0.001) and at 10
-9M (p = 0.034) after 120
h, however the latter increase was smaller than the
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Figure 4 ALP levels after treatments with gut hormones in three osteoblastic cell lines. Cells were treated for 48 or 120 h with modified
medium containing the gut peptides at indicated molar concentrations. Straight lines circle solid markers designate 48 h treatment; dashed lines
emptied circle markers indicate 120 h treatment. Only Saos-2 and TE-85 displayed statistically significant responses to gut peptides in ALP
production. Saos-2 responded to GIP (C), GHR (L) and OB (O). TE-85 was stimulated only by GHR (K). MG-63 did not show any significant
changes. Results are the average of percentage of change in relation to controls; n = 10, ± SEM.
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Page 8 of 14former (Figure 5O). MG-63 registered a decrease but
this was not significant (Figure 5M).
Osteocalcin secretion
The results for this assay corresponded only to those
obtained from MG-63 experiments. The reason was that
Saos-2 and TE-85 did not produce significant amounts
of this protein, and there was a minimum difference
when compared against blanks (medium from wells con-
taining no cells). However, OC from MG-63 cultures
were significantly different from the blanks making MG-
63 the only cell line in this study that could be used as
a model to investigate the production of this protein in
vitro.
No statistically significant differences were found after
stimulation with GIP, GLP-1, GHR and OB (Figure 6A,
B, D, and 6E). However, GLP-2 caused different patterns
in OC production depending upon the time of exposure:
after 48 h a significant increase was observed with the
lowest concentration of the hormone (p = 0.033), and
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Figure 5 P1NP levels after treatments with gut hormones in three osteoblastic cell lines. Cells were serum deprived and treated for 48 or
120 h with the gut peptides at indicated molar concentrations. Straight lines solid square markers designate 48 h treatment; dashed lines
emptied square markers indicate 120 h treatment. Significant higher production of P1NP after 120 h exposure to GIP and OB were observed
only in Saos-2 (C, O). The least mature cell lines, MG-63 and TE-85 showed decreased P1NP secretion in response to GIP (A), GLP-1 (D, E), GLP-2
(H) and OB (N) stimulation after 120 h exposure. In all the cases the most significant changes were observed with the lowest concentration of
peptide. Results are the average of percentage of change in relation to controls; n = 5. ± SEM.
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tration but a plateau was established. After 120 h expo-
sure, a significant decrease was observed at low
concentration (p = 0.032) and no significant changes
were observed with the high concentration, but the per-
centage of change was below the control (Figure 6C).
Discussion
This work presents a study of the receptors for the gut
hormones GIP, GLP-1, GLP-2, GHR and OB, in three
osteoblastic cell lines. The chosen in vitro model repre-
sents different stages of osteoblastic development and
has been valuable in analysing the patterns of expression
of the genes of interest in different levels of osteoblastic
maturity. Although investigation of cell lines may differ
in some responses from naturally occurring primary
cells the use of cell lines represents a suitable model to
study determined characteristics in a specific stage of
osteoblast maturity as an initial observation.
COL1A2, ALP and OPG mRNA expression were used
as bone markers that are correlated with osteoblastic
differentiation. It has been shown that type 1 collagen
mRNA signal increases according to the degree of dif-
ferentiation in cultured rat calvaria cells [31]. ALP is
associated with the phase of differentiation and stabilisa-
tion of mineralised matrix [32]; OPG mRNA expression
has been found to be increased during matrix produc-
tion and maturation in rat calvaria cultures [33]. The
results confirmed that TE-85 and Saos-2 had the highest
levels of relative expression for COL1A2 compared to
MG-63. ALP mRNA also showed its highest expression
in Saos-2 and lowest in MG-63. OPG mRNA levels
were similar in TE-85 and Saos-2, (2.5 and 2.6 fold
respectively), and MG-63 expressed the lowest levels.
This suggests that Saos-2 is the most mature; MG-63 is
the least mature of the cell lines and TE-85 intermediate
between the other two.
GIP-R has been described in chondrocytes, osteocytes,
osteoblasts and in two of the cell lines studied here
(MG-63 and Saos-2) [7,20], however the novelty of this
current work is the profile of expression for those recep-
tors which may be evident in different stages of maturity
and correlated with the maturity of the cell lines. MG-
63 and Saos-2 express GHS-R but no visual differences
were demonstrated in earlier qualitative PCR screening
[20]. Also GHS-R peaked three days after induction of
osteoblastic differentiation of a murine cell line and the
expression decreased with time, i.e. in more mature
osteoblasts. In the current work GHS-R expression was
greatest in the cell lines representing early osteoblasts
(MG-63 and TE-85), while the most mature showed the
l o w e s te x p r e s s i o n ,i nk e e p i n gw i t ht h et i m ec o u r s eo f
expression shown in the previous report. GHR has been
shown to induce direct responses in bone cells through
its receptor, in several different ways: differentiation,
proliferation and/or viability [19-21].
GLP-1R had not previously been reported in human
osteoblasts, or in osteoblastic cell lines like MG-63 or
Saos-2 [7,12] but lately a study detected the presence of
a functional receptor in a murine cell line, independent
of the cAMP linked receptor [13] which is different
f r o mt h eh u m a no n ew ed e s c r i b e di nt h i sp a p e r .W e
indeed confirmed that Saos-2 cells do not express the
receptor we looked for. However, TE-85 and MG-63
were positive for GLP-1R. The reasons for the discre-
pant results in MG-63 are not clear, but an explanation
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template: smaller templates show more efficiency when
they are amplified [34,35]. In the present work, the size
of the template was much smaller (114 bp) than the size
used in the previous report (695 bp), because qPCR
calls for small templates. One study [12] showed that in
a knockout animal model lacking GLP-1R, cortical BMD
at tibia and lumbar spine was significantly reduced.
They also established the lack of effects of GLP-1 treat-
ment on Saos-2 cultures, which is in agreement with the
current study demonstrating lack of GLP-1R.
The authors proposed that GLP-1R is essential in the
control of bone resorption indirectly, since this receptor
is expressed in thyroid C cells, and GLP-1 is able to sti-
mulate calcitonin production in those cells with calcito-
nin receptor being able to inhibit osteoclastic bone
resorption. No studies have confirmed GLP-2R presence
either in osteoblastic or osteoclastic cells, and only two
short reports mention its existence in bone-related cells
[36,37], in contrast, the effects on bone resorption after
administration of the peptide in clinical trials have been
well documented [17,38,39]. GPR39 is believed to be the
receptor for obestatin [22,40], but some reports have
questioned that possibility [24,41,42]. A study demon-
strated that transformed human embryonic kidney cells
(293T) when transfected with a plasmid encoding
human or mouse GPR39, but not GHS-R, exhibited
high-affinity binding to an analogue of obestatin (mono-
iodobestatin) [26]. These receptors have not been
described in bone-related cells, and the only record is
listed in GenBank reporting its presence in a chondro-
sarcoma cell line (CA749039.1). In this current work
PCR reactions showed positive signals for the receptor
however the relationship between this receptor, obesta-
tin and their influence on bone should be interpreted
with caution.
Regarding functional responses, Saos-2 exhibited the
most significant changes following exposure to GIP in
terms of increases in cell viability, ALP secretion and
P1NP production, according to the level of expression
for this receptor. GHR and OB also induced significantly
higher levels of ALP activity in Saos-2. In addition, it
h a sb e e nd e m o n s t r a t e dt h a tG I Pa n dG H R ,a r ea b l et o
induce functional responses in osteoblast-like cells [5],
or to promote bone formation [19,21]. These observa-
tions are consistent with the findings in this study,
showing responses at the concentrations from 10
-12 to
10
-9M. This is relevant in relation to the physiological
response in vivo as these concentrations are equivalent
to the plasma levels that these hormones reach after
meals [38,43,44]. However, a cautious note on this find-
ing is the fact that a significant change in ALP activity is
an indicator that a change in bone cell activity is taking
place, and not only suggestive of bone formation as it
has been demonstrated that increased values are asso-
ciated with bone loss in aging, osteoporosis and meno-
pause [45]. Levels of this enzyme decrease with therapy
antiresorptive agents [46], but can increase again in
response to anabolic treatments like teriparatide (recom-
binant form of PTH) [47].
MG-63 and TE-85, representing younger osteoblasts,
showed significant higher levels of cell viability when
the cell cultures were incubated in the presence of GLP-
1 or GLP-2, as they showed higher expressions for these
receptors. However they did not display any significant
changes in terms of ALP secretion and TE-85 only
responded to GHR at its highest concentration (10
-9M).
This lack of response might be attributable to lower
ALP synthesis (as assessed by the relative level of ALP
mRNA expression) rather than an absence of stimula-
tion. No major changes were demonstrated for Saos-2,
confirming the lack of the receptors in these cells.
Decreased P1NP concentrations were observed in
supernatants from early osteoblasts-like (MG-63 and
TE-85) after long exposure to GIP, GLP-1, GLP-2, OB
in TE-85 and after GLP-1 in MG-63 cells. Short expo-
sure did not cause significant changes and a sustained
stimulation displayed a negative effect. The possibility
that this pattern was caused because cell health was
compromised can be rejected, as the viability assay did
not show any significant cell death after long exposure
to the peptides. Thus the changes in P1NP production,
either by P1NP degradation or a decreased production
of collagen, by the cell lines were caused by the pre-
sence of the peptides. There are no studies reporting
changes in P1NP production by cells in vitro in
response to these peptides and this is the first study to
examine this bone marker in these cell lines. Conversely,
Saos-2 cells showed significant increases of P1NP levels
following GIP and OB. This is consistent with the stu-
dies that show GIP stimulates bone formation
[5,9,48,49]. These opposite effects in response to GIP,
increased levels in Saos-2 and decreased concentrations
in TE-85, can be related to other findings which after
prolonged exposure to high concentrations of GIP there
was downregulation of the GIP-R in Saos-2 cells [5].
This finding may underpin the results observed in TE-
85 and may account for the modest decrease of P1NP
observed in MG-63 at the highest GIP concentration.
On one hand GIP can promote bone formation (which
is consistent with the results shown here for Saos-2 in
terms of ALP and P1NP increases), but also a downre-
gulation of the receptor might be a feasible explanation
for the decreasing levels found in TE-85 after longer
exposure to higher concentrations of the peptide.
It has been repeatedly reported that GLP-1R is not
present in osteoblasts, but it should be noted that the
published data refer mainly to the studies performed
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receptor. TE-85 and MG-63 express the receptor and
exhibited some significant responses to this peptide in
the viability assay, and in P1NP secretion after long
exposure to GLP-1. These observations support previous
studies which show the role of GLP-1R in the mediation
of bone resorption [12] and the possible association of
GLP-1 treatment with the improvement in bone disor-
ders linked to glucose intolerance [11]. While the
reports linking GLP-1 to bone activity are few, there are
more studies showing effects of GLP-2 in bone, and all
of them found reductions in bone resorption markers,
in clinical trials [17,38,39,50]. In the current work, the
responses to GLP-2 were observed in TE-85 and MG-
63, with significant decreased secretion of P1NP and
OC. Most clinical trials have not shown any significant
difference in the levels of those markers after treatment
with GLP-2 [16,39,50]. Here, GLP-2 produced a signifi-
cant response in TE-85 decreasing P1NP and in MG-63
caused a significant increase after 48 h and a significant
decrease after 120 h. No regulation of the receptor has
been suggested in previous reports.
GHR can induce responses from bone-related cells in
vitro [19-21]. We confirmed these findings and a signifi-
cant increase of ALP was found in Saos-2 and TE-85
but no significant changes were found at any time point
f o rP 1 N Po rO C .W er e g a r dt h a tG H Rm a yb ea n
important modulator in the cells with a higher degree of
differentiation, although the expression was more
important in MG-63, these cells did not respond signifi-
cantly to this peptide in any of the tests. In agreement
with the latter experimental data, there is a clinical
study reporting no significant effects of a GHR infusion
on plasma CTX or P1NP when healthy and post-gas-
trectomy patients were studied [51] but an inverse rela-
tionship existed between baseline plasma GHR and
CTX, suggesting that GHR may have a role regulating
bone resorption.
OB caused significant ALP and P1NP increases in
Saos-2, but TE-85 displayed decreased responses. The
only data on OB effects is a short report where a
human chondrocyte cell line, C28-I2, was studied and
no changes were found in ALP production [52]. Some
contradictory results have been reported where pancrea-
tic beta cells displayed higher levels of survival after OB
treatment [53] and no effect on cadiomyocytes viability
was observed [54].
These paradoxical results, also observed in some of
the clinical trials, may be explained by the nature of the
receptor for these ligands which belong to the G protein
coupled receptors and may be desensitised after long
exposure to the ligand. In the case of GIP in Saos-2 a
significant increase with the lowest concentration, might
be explained by changes in receptor expression. Because
the receptors for the hormones studied are GPCR, they
can be subjected to some desensitization or rapid
attenuation of receptor sensitivity after exposure to ago-
nists [55].
Conclusions
Given all the observations, it is tempting to hypothesise
that osteoblastic cells respond to the gut peptides stimuli
in feeding/fasting states depending on their stage of dif-
ferentiation and on the duration of exposure to the gut
hormones. In this way, the activity of bone cells is
affected since the neuronal stimulus to eat is triggered,
r e p r e s e n t e di nt h i si n s t a n c eb yG H R ,a n di su n d e rt h e
influence of nutrients transiting through the gastrointest-
inal tract. The regulation of the gut receptors on bone
could be another mechanism in the modulating bone
metabolism. The behaviour of the osteoblastic cells in
presence of peptides may vary with downregulation due
to either sustained exposure or high circulating concen-
trations or both, since these receptors are GPCRs and
they are able to decrease the responses to stimuli by sev-
eral mechanisms that minimise the reaction to the ligand.
The ultimate goal of this research was to study the
differential responses from the cell model, once the pre-
sence of receptors was assessed. However, further trans-
lational proteomics to explore the development through
a primary cell osteoblastic development should be in
order for prospective work.
In summary, we have shown that osteoblast-like cells
express the receptors for five gut hormones, and they
exhibit contrasting reactions when the correspondent
ligands are present in the cell cultures.
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